TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00135135

Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid
Description: See Detailed Description.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation therapy, Surgery, Peripheral Stem cell transplant
Description: See Detailed Description.
Study: NCT03009006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
Study: NCT03246217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Performance with Sensory-Enhanced Motor Imagery
Description: Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
Study: NCT03009006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
Study: NCT03246217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Performance with Motor Imagery
Description: Participants will engage in motor imagery of previously practised movements.
Study: NCT02050308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-All Nations Breath of Life (I-ANBL)
Description: * Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~* Weekly procedures will follow the same format as for the first session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Honoring the Gift of Heart Health
Description: These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®
Description: Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®
Description: Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
Study: NCT02710149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD20-CAR-transduced T cells
Description: Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
Study: NCT01986686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon resection
Description: Elective robotic/laparoscopic/open colon resection for diverticular disease.
Study: NCT00987961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage
Description: This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
Study: NCT02787941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered multifaceted intervention
Description: First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding.
Study: NCT00740155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD-1,2,3,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
Study: NCT02667249

Intervention type: OTHER
Intervention: clinical pathway
Description: implementation of a standardized clinical pathway

Intervention type: OTHER
Intervention: clinical pathway
Description: implementation of a standardized clinical pathway
Study: NCT04669041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC ezetimibe/rosuvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin active capsule
Description: Pharmaceutical form:Capsule Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study: NCT03514758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: several virtual 3-D complex audio environments
Description: The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
Study: NCT00111956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study: NCT04650048

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active HD-tDCS
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham HD-tDCS
Description: Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS.
Study: NCT04353830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI939
Description: Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI939+ Sintilimab
Description: IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI939+ Sintilimab
Description: IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit.
Study: NCT00939042

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: common Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMNC therapy
Description: Injection of BMNC after common PCI
Study: NCT01581736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U100 Humulin
Description: Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Single episode of exercise riding a stationary bike.
Study: NCT01256034

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
Study: NCT00711919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
Study: NCT03308461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota suspension
Description: The prepared microbiota suspension was infused into mid-gut.
Study: NCT04493242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
Study: NCT04185480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
Study: NCT02940626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN100
Description: monoclonal antibody combination of ASN-1 and ASN-2
Study: NCT04493242

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline
Description: Placebo
Study: NCT01726530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal fentanyl patch (50 mcg/hour)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01456819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear and mesenchymal stem cells
Description: Intramuscular administration into the ischemic limb

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mononuclear cells
Description: Intramuscular administration into the ischemic limb
Study: NCT00111956

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02940626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00982241

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: drinking water / normal dietary fluids for oral intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: drinking water / normal dietary fluids for oral intake
Study: NCT02187900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)
Description: The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
Study: NCT02717299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verasense
Description: Verasense will collect balancing data on all patients in this trial.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Verasense
Description: Verasense will collect balancing data on all patients in this trial.
Study: NCT00079183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study: NCT02120313

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inpatient rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: outpatient rehabilitation
Study: NCT00993850

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy for insomnia
Description: Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
Study: NCT00982241

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: drinking water / normal dietary fluids for oral intake
Study: NCT02006667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
Study: NCT03529643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Anesthesia with sevoflurane-remifentanil-dexmedetomidine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without dexmedetomidine
Description: Anesthesia with sevoflurane-remifentanil
Study: NCT02006667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
Study: NCT02132234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: biological treatment according to rheumatologic indication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: biological treatment according to rheumatologic indication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Description: biological treatment according to rheumatologic indication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: biological treatment according to rheumatologic indication
Study: NCT02437448

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT01503073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
Description: transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
Description: transcranial direct current stimulation
Study: NCT04598581

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Radiation Therapy (LD-RT)
Description: Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham irradiation
Description: Sham irradiation
Study: NCT04213872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditative Movement
Description: The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
Study: NCT02987764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cord milking
Description: For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
Study: NCT02776657

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
Study: NCT00538291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study: NCT00993850

Intervention type: OTHER
Group type: OTHER
Intervention: Bipolar education
Description: Psychoeducation
Study: NCT04643236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodontal health education session
Description: This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
Study: NCT00524862

Intervention type: DRUG
Group type: OTHER
Intervention: Optimized medical therapy
Description: Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator
Description: an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
Study: NCT03494959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentaglobin
Description: Antimicrobial treatment active against the multidrug-resistant strain should be started in case of neutropenic fever (oral temperature ≥38.3°C or temperature ≥38.0°C sustained over a one-hour period). Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days. Empirical treatment should be subsequently streamlined according to microbiological results (both positive and negative). Pentaglobin should be started within 12h from the onset of fever, regardless of the presence of hemodynamic stability.